This is the first competing continuation application for the Vanderbilt Cancer Center (VCC) CCSG. The VCC is a matrix center within Vanderbilt University Medical Center (VUMC), and the VCC integrates the cancer-related expertise and resources of the School of Medicine, Vanderbilt University Hospital, and The Vanderbilt Clinic within VUMC; the fully integrated Veterans Administration Medical Center (VAMC); and the Departments of Chemistry and Molecular Biology in the School of Arts and Sciences. All facilities are located in close proximity on the same campus, a situation that promotes interactions, sharing of resources, and collaborations. Established in 1993, the VCC functions as an organizational unit with a supradepartmental status. The VCC s specific authorities and responsibilities are: 1) to coordinate and integrate the cancer and cancer-related activities of Vanderbilt University; 2) to conduct, support and enhance cancer research and to integrate cancer-related activities throughout the University; 3) to integrate, develop and conduct cancer education programs; and 4) to coordinate and integrate the care of cancer patients at VUMC and VAMC. The research objectives are accomplished through seven research programs: Signal Transduction and Cell Proliferation, Cancer Genetics and Genomics, Host Tumor Interactions, Gastrointestinal Cancer, Breast Cancer, Cancer Prevention, and Experimental Therapeutics. Because of new directions and opportunities, the research programs have been reorganized and refined. Significantly, a Cancer Prevention Research Program has been developed with the anticipation of obtaining comprehensive status. Following the reorganization of the research programs, the entire membership of the VCC was evaluated by a stringent set of criteria, and members were assigned to research programs by the individual program leaders or their membership terminated. Eleven shared resources are proposed representing reorganization of clinical research-related shared resources, establishment of two new ones and termination of one. Since the submission of our initial CCSG application in 1994, the VCC has participated in the recruitment of 29 faculty members to enhance programs or shared resources. Start-up funding for 13 of these faculty was provided by the VCC; the remaining 16 were supported initially by institutional or departmental funds with the VCC identifying or helping to identify the need and playing a major role in the recruitment process.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA068485-05S2
Application #
6353334
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1995-09-05
Project End
2004-08-31
Budget Start
2000-09-01
Budget End
2001-08-31
Support Year
5
Fiscal Year
2000
Total Cost
$326,074
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Dahlman, Kimberly Brown; Weinger, Matthew B; Lomis, Kimberly D et al. (2018) Integrating Foundational Sciences in a Clinical Context in the Post-Clerkship Curriculum. Med Sci Educ 28:145-154
Covington, Brett C; Spraggins, Jeffrey M; Ynigez-Gutierrez, Audrey E et al. (2018) Response of Hypogean Actinobacterial Genera Secondary Metabolism to Chemical and Biological Stimuli. Appl Environ Microbiol :
Hong, Jun; Maacha, Selma; Belkhiri, Abbes (2018) Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma. Mol Oncol 12:2191-2208
Bolus, W Reid; Peterson, Kristin R; Hubler, Merla J et al. (2018) Elevating adipose eosinophils in obese mice to physiologically normal levels does not rescue metabolic impairments. Mol Metab 8:86-95
Ramsey, Haley E; Fischer, Melissa A; Lee, Taekyu et al. (2018) A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discov 8:1566-1581
Wu, Jie; Cai, Hui; Xiang, Yong-Bing et al. (2018) Intra-individual variation of miRNA expression levels in human plasma samples. Biomarkers 23:339-346
Cardin, Dana B; Goff, Laura W; Chan, Emily et al. (2018) Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs 36:442-450
Yang, Jinming; Kumar, Amrendra; Vilgelm, Anna E et al. (2018) Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms. Cancer Immunol Res 6:1186-1198
Alvarado, Gabriela; Ettayebi, Khalil; Atmar, Robert L et al. (2018) Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses. Gastroenterology 155:1898-1907
Sierra, Johanna C; Asim, Mohammad; Verriere, Thomas G et al. (2018) Epidermal growth factor receptor inhibition downregulates Helicobacter pylori-induced epithelial inflammatory responses, DNA damage and gastric carcinogenesis. Gut 67:1247-1260

Showing the most recent 10 out of 2462 publications